Novocure (NVCR) said Monday it received a Not Approvable Letter from the US Food and Drug Administration for its Optune Mya device to treat adults with brain metastases from non-small cell lung cancer following stereotactic radiation.
The company said the FDA determined that uncertainty about the degree of clinical benefit prevented approval of its premarket approval application but raised no concerns about the device's safety profile.
Novocure said it is evaluating the agency's feedback and plans to meet with the agency to discuss potential paths to approval that would not require additional clinical studies.
The company added that there is no guarantee the discussions or any future submissions will result in approval.
Shares of the company fell more than 4% in Monday's premarket activity.
Comments